Study agents | Other agents | Disease | Dose | Trials | No. of Pts | Response | Reference |
---|---|---|---|---|---|---|---|
Bendamustine | chlorambucil | Untreated | 100 mg/m2 | Phase III | 305 | CR:29% | [22] |
ORR:68% | |||||||
Bendamustine | Rituximab | Untreated | 60-100 mg/m2 | Retrospective | 142 | CR:19% | [23] |
High risk | ORR:80% | ||||||
Relapsed | |||||||
Refractory | |||||||
Bendamustine | Rituximab | Untreated | 133.6-165.9 | Retrospective | 217 | CR>19% | [24] |
Prednisone | mg/m2 | ORR>83% | |||||
Bendamustine | Alemtuzumab | Relapsed | 50-70 mg/m2 | Retrospective | 50 | CR:26% | [25] |
Refractory | ORR:70% | ||||||
Bendamustine | Fludarabine | High risk | 20-50Â mg/m2 | Phase I/II | 35 | CR/CRi:26% | [26] |
Rituximab | Relapsed | ORR:71% | |||||
 |  | Refractory |  |  |  |  |  |